

Global Alpha- Antitrypsin Deficiency Treatment Market Growth (Status and Outlook) 2024-2030

<https://marketpublishers.com/r/G1319C0229CDEN.html>

Date: February 2024

Pages: 126

Price: US\$ 3,660.00 (Single User License)

ID: G1319C0229CDEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Alpha- Antitrypsin Deficiency Treatment market size was valued at US\$ 1820.1 million in 2023. With growing demand in downstream market, the Alpha- Antitrypsin Deficiency Treatment is forecast to a readjusted size of US\$ 3399.8 million by 2030 with a CAGR of 9.3% during review period.

The research report highlights the growth potential of the global Alpha- Antitrypsin Deficiency Treatment market. Alpha- Antitrypsin Deficiency Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Alpha- Antitrypsin Deficiency Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Alpha- Antitrypsin Deficiency Treatment market.

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener's granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs

(emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Key Features:

The report on Alpha- Antitrypsin Deficiency Treatment market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Alpha- Antitrypsin Deficiency Treatment market. It may include historical data, market segmentation by Type (e.g., CT-2009, POL-6014), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Alpha- Antitrypsin Deficiency Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry,

including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Alpha- Antitrypsin Deficiency Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Alpha- Antitrypsin Deficiency Treatment industry. This include advancements in Alpha- Antitrypsin Deficiency Treatment technology, Alpha- Antitrypsin Deficiency Treatment new entrants, Alpha- Antitrypsin Deficiency Treatment new investment, and other innovations that are shaping the future of Alpha- Antitrypsin Deficiency Treatment.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Alpha- Antitrypsin Deficiency Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Alpha- Antitrypsin Deficiency Treatment product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Alpha- Antitrypsin Deficiency Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Alpha- Antitrypsin Deficiency Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Alpha- Antitrypsin Deficiency Treatment market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Alpha- Antitrypsin Deficiency Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Alpha- Antitrypsin Deficiency Treatment market.

Market Segmentation:

Alpha- Antitrypsin Deficiency Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Segmentation by type

CT-2009

POL-6014

ARO-AAT

ALNAAT-02

Others

Segmentation by application

Clinic

Hospital

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Adverum Biotechnologies, Inc.

Alnylam Pharmaceuticals, Inc.

Applied Genetic Technologies Corporation

Arrowhead Pharmaceuticals, Inc.

Carolus Therapeutics, Inc.

Cevec Pharmaceuticals GmbH

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

Editas Medicine, Inc.

Grifols, S.A.

Inhibrx

Intellia Therapeutics, Inc.

International Stem Cell Corporation

Ionis Pharmaceuticals, Inc.

Kamada Ltd.

Polyphor Ltd.

ProMetic Life Sciences Inc.

rEVO Biologics, Inc.

Sangamo BioSciences, Inc.

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size 2019-2030
 - 2.1.2 Alpha- Antitrypsin Deficiency Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
- 2.2 Alpha- Antitrypsin Deficiency Treatment Segment by Type
 - 2.2.1 CT-2009
 - 2.2.2 POL-6014
 - 2.2.3 ARO-AAT
 - 2.2.4 ALNAAT-02
 - 2.2.5 Others
- 2.3 Alpha- Antitrypsin Deficiency Treatment Market Size by Type
 - 2.3.1 Alpha- Antitrypsin Deficiency Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
 - 2.3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)
- 2.4 Alpha- Antitrypsin Deficiency Treatment Segment by Application
 - 2.4.1 Clinic
 - 2.4.2 Hospital
 - 2.4.3 Others
- 2.5 Alpha- Antitrypsin Deficiency Treatment Market Size by Application
 - 2.5.1 Alpha- Antitrypsin Deficiency Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
 - 2.5.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

3 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE BY PLAYER

3.1 Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Players

3.1.1 Global Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2019-2024)

3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT BY REGIONS

4.1 Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (2019-2024)

4.2 Americas Alpha- Antitrypsin Deficiency Treatment Market Size Growth (2019-2024)

4.3 APAC Alpha- Antitrypsin Deficiency Treatment Market Size Growth (2019-2024)

4.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size Growth (2019-2024)

4.5 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Growth (2019-2024)

5 AMERICAS

5.1 Americas Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)

5.2 Americas Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024)

5.3 Americas Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2019-2024)

6.2 APAC Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024)

6.3 APAC Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Alpha- Antitrypsin Deficiency Treatment by Country (2019-2024)

7.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024)

7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment by Region (2019-2024)

8.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024)

8.3 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET FORECAST

10.1 Global Alpha- Antitrypsin Deficiency Treatment Forecast by Regions (2025-2030)

10.1.1 Global Alpha- Antitrypsin Deficiency Treatment Forecast by Regions (2025-2030)

10.1.2 Americas Alpha- Antitrypsin Deficiency Treatment Forecast

10.1.3 APAC Alpha- Antitrypsin Deficiency Treatment Forecast

10.1.4 Europe Alpha- Antitrypsin Deficiency Treatment Forecast

10.1.5 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Forecast

10.2 Americas Alpha- Antitrypsin Deficiency Treatment Forecast by Country (2025-2030)

10.2.1 United States Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.2.2 Canada Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.2.3 Mexico Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.2.4 Brazil Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.3 APAC Alpha- Antitrypsin Deficiency Treatment Forecast by Region (2025-2030)

10.3.1 China Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.3.2 Japan Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.3.3 Korea Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.3.4 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.3.5 India Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.3.6 Australia Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.4 Europe Alpha- Antitrypsin Deficiency Treatment Forecast by Country (2025-2030)

10.4.1 Germany Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.4.2 France Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.4.3 UK Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.4.4 Italy Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.4.5 Russia Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.5 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Forecast by Region (2025-2030)

10.5.1 Egypt Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.5.2 South Africa Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.5.3 Israel Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.5.4 Turkey Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.5.5 GCC Countries Alpha- Antitrypsin Deficiency Treatment Market Forecast

10.6 Global Alpha- Antitrypsin Deficiency Treatment Forecast by Type (2025-2030)

10.7 Global Alpha- Antitrypsin Deficiency Treatment Forecast by Application
(2025-2030)

11 KEY PLAYERS ANALYSIS

11.1 Adverum Biotechnologies, Inc.

11.1.1 Adverum Biotechnologies, Inc. Company Information

11.1.2 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product
Offered

11.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment
Revenue, Gross Margin and Market Share (2019-2024)

11.1.4 Adverum Biotechnologies, Inc. Main Business Overview

11.1.5 Adverum Biotechnologies, Inc. Latest Developments

11.2 Alnylam Pharmaceuticals, Inc.

11.2.1 Alnylam Pharmaceuticals, Inc. Company Information

11.2.2 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product
Offered

11.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment
Revenue, Gross Margin and Market Share (2019-2024)

11.2.4 Alnylam Pharmaceuticals, Inc. Main Business Overview

11.2.5 Alnylam Pharmaceuticals, Inc. Latest Developments

11.3 Applied Genetic Technologies Corporation

11.3.1 Applied Genetic Technologies Corporation Company Information

11.3.2 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency
Treatment Product Offered

11.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency
Treatment Revenue, Gross Margin and Market Share (2019-2024)

11.3.4 Applied Genetic Technologies Corporation Main Business Overview

11.3.5 Applied Genetic Technologies Corporation Latest Developments

11.4 Arrowhead Pharmaceuticals, Inc.

11.4.1 Arrowhead Pharmaceuticals, Inc. Company Information

11.4.2 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment
Product Offered

11.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment
Revenue, Gross Margin and Market Share (2019-2024)

11.4.4 Arrowhead Pharmaceuticals, Inc. Main Business Overview

11.4.5 Arrowhead Pharmaceuticals, Inc. Latest Developments

11.5 Carolus Therapeutics, Inc.

- 11.5.1 Carolus Therapeutics, Inc. Company Information
- 11.5.2 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered
- 11.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 Carolus Therapeutics, Inc. Main Business Overview
- 11.5.5 Carolus Therapeutics, Inc. Latest Developments
- 11.6 Cevec Pharmaceuticals GmbH
- 11.6.1 Cevec Pharmaceuticals GmbH Company Information
- 11.6.2 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Offered
- 11.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 Cevec Pharmaceuticals GmbH Main Business Overview
- 11.6.5 Cevec Pharmaceuticals GmbH Latest Developments
- 11.7 Dicerna Pharmaceuticals, Inc.
- 11.7.1 Dicerna Pharmaceuticals, Inc. Company Information
- 11.7.2 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered
- 11.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 11.7.4 Dicerna Pharmaceuticals, Inc. Main Business Overview
- 11.7.5 Dicerna Pharmaceuticals, Inc. Latest Developments
- 11.8 Digna Biotech, S.L.
- 11.8.1 Digna Biotech, S.L. Company Information
- 11.8.2 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Offered
- 11.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 11.8.4 Digna Biotech, S.L. Main Business Overview
- 11.8.5 Digna Biotech, S.L. Latest Developments
- 11.9 Editas Medicine, Inc.
- 11.9.1 Editas Medicine, Inc. Company Information
- 11.9.2 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered
- 11.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 11.9.4 Editas Medicine, Inc. Main Business Overview
- 11.9.5 Editas Medicine, Inc. Latest Developments
- 11.10 Grifols, S.A.
- 11.10.1 Grifols, S.A. Company Information

- 11.10.2 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Offered
- 11.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 11.10.4 Grifols, S.A. Main Business Overview
- 11.10.5 Grifols, S.A. Latest Developments
- 11.11 Inhibrx
 - 11.11.1 Inhibrx Company Information
 - 11.11.2 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Offered
 - 11.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
 - 11.11.4 Inhibrx Main Business Overview
 - 11.11.5 Inhibrx Latest Developments
- 11.12 Intellia Therapeutics, Inc.
 - 11.12.1 Intellia Therapeutics, Inc. Company Information
 - 11.12.2 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered
 - 11.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
 - 11.12.4 Intellia Therapeutics, Inc. Main Business Overview
 - 11.12.5 Intellia Therapeutics, Inc. Latest Developments
- 11.13 International Stem Cell Corporation
 - 11.13.1 International Stem Cell Corporation Company Information
 - 11.13.2 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Offered
 - 11.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
 - 11.13.4 International Stem Cell Corporation Main Business Overview
 - 11.13.5 International Stem Cell Corporation Latest Developments
- 11.14 Ionis Pharmaceuticals, Inc.
 - 11.14.1 Ionis Pharmaceuticals, Inc. Company Information
 - 11.14.2 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered
 - 11.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)
 - 11.14.4 Ionis Pharmaceuticals, Inc. Main Business Overview
 - 11.14.5 Ionis Pharmaceuticals, Inc. Latest Developments
- 11.15 Kamada Ltd.
 - 11.15.1 Kamada Ltd. Company Information
 - 11.15.2 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Offered

11.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)

11.15.4 Kamada Ltd. Main Business Overview

11.15.5 Kamada Ltd. Latest Developments

11.16 Polyphor Ltd.

11.16.1 Polyphor Ltd. Company Information

11.16.2 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Offered

11.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)

11.16.4 Polyphor Ltd. Main Business Overview

11.16.5 Polyphor Ltd. Latest Developments

11.17 ProMetic Life Sciences Inc.

11.17.1 ProMetic Life Sciences Inc. Company Information

11.17.2 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

11.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)

11.17.4 ProMetic Life Sciences Inc. Main Business Overview

11.17.5 ProMetic Life Sciences Inc. Latest Developments

11.18 rEVO Biologics, Inc.

11.18.1 rEVO Biologics, Inc. Company Information

11.18.2 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

11.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)

11.18.4 rEVO Biologics, Inc. Main Business Overview

11.18.5 rEVO Biologics, Inc. Latest Developments

11.19 Sangamo BioSciences, Inc.

11.19.1 Sangamo BioSciences, Inc. Company Information

11.19.2 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

11.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2024)

11.19.4 Sangamo BioSciences, Inc. Main Business Overview

11.19.5 Sangamo BioSciences, Inc. Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Alpha- Antitrypsin Deficiency Treatment Market Size CAGR by Region (2019 VS 2023 VS 2030) & (\$ Millions)

Table 2. Major Players of CT-2009

Table 3. Major Players of POL-6014

Table 4. Major Players of ARO-AAT

Table 5. Major Players of ALNAAT-02

Table 6. Major Players of Others

Table 7. Alpha- Antitrypsin Deficiency Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030) & (\$ Millions)

Table 8. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 9. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

Table 10. Alpha- Antitrypsin Deficiency Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030) & (\$ Millions)

Table 11. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

Table 13. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2019-2024) & (\$ Millions)

Table 14. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Player (2019-2024)

Table 15. Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Products Offered

Table 16. Alpha- Antitrypsin Deficiency Treatment Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

Table 17. New Products and Potential Entrants

Table 18. Mergers & Acquisitions, Expansion

Table 19. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions 2019-2024 & (\$ Millions)

Table 20. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Regions (2019-2024)

Table 21. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Country/Region (2019-2024) & (\$ millions)

Table 22. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Country/Region (2019-2024)

Table 23. Americas Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2019-2024) & (\$ Millions)

Table 24. Americas Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Country (2019-2024)

Table 25. Americas Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 26. Americas Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

Table 27. Americas Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 28. Americas Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

Table 29. APAC Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2019-2024) & (\$ Millions)

Table 30. APAC Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Region (2019-2024)

Table 31. APAC Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 32. APAC Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

Table 33. APAC Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 34. APAC Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

Table 35. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2019-2024) & (\$ Millions)

Table 36. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Country (2019-2024)

Table 37. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 38. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

Table 39. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 40. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

Table 41. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by

Region (2019-2024) & (\$ Millions)

Table 42. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Region (2019-2024)

Table 43. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2019-2024) & (\$ Millions)

Table 44. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

Table 45. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2019-2024) & (\$ Millions)

Table 46. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

Table 47. Key Market Drivers & Growth Opportunities of Alpha- Antitrypsin Deficiency Treatment

Table 48. Key Market Challenges & Risks of Alpha- Antitrypsin Deficiency Treatment

Table 49. Key Industry Trends of Alpha- Antitrypsin Deficiency Treatment

Table 50. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Regions (2025-2030) & (\$ Millions)

Table 51. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share Forecast by Regions (2025-2030)

Table 52. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Type (2025-2030) & (\$ Millions)

Table 53. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Application (2025-2030) & (\$ Millions)

Table 54. Adverum Biotechnologies, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 55. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 56. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 57. Adverum Biotechnologies, Inc. Main Business

Table 58. Adverum Biotechnologies, Inc. Latest Developments

Table 59. Alnylam Pharmaceuticals, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 60. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 61. Alnylam Pharmaceuticals, Inc. Main Business

Table 62. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 63. Alnylam Pharmaceuticals, Inc. Latest Developments

Table 64. Applied Genetic Technologies Corporation Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 65. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 66. Applied Genetic Technologies Corporation Main Business

Table 67. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 68. Applied Genetic Technologies Corporation Latest Developments

Table 69. Arrowhead Pharmaceuticals, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 70. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 71. Arrowhead Pharmaceuticals, Inc. Main Business

Table 72. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 73. Arrowhead Pharmaceuticals, Inc. Latest Developments

Table 74. Carolus Therapeutics, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 75. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 76. Carolus Therapeutics, Inc. Main Business

Table 77. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 78. Carolus Therapeutics, Inc. Latest Developments

Table 79. Cevec Pharmaceuticals GmbH Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 80. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 81. Cevec Pharmaceuticals GmbH Main Business

Table 82. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 83. Cevec Pharmaceuticals GmbH Latest Developments

Table 84. Dicerna Pharmaceuticals, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 85. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 86. Dicerna Pharmaceuticals, Inc. Main Business

Table 87. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 88. Dicerna Pharmaceuticals, Inc. Latest Developments
Table 89. Digna Biotech, S.L. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors
Table 90. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Offered
Table 91. Digna Biotech, S.L. Main Business
Table 92. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 93. Digna Biotech, S.L. Latest Developments
Table 94. Editas Medicine, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors
Table 95. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered
Table 96. Editas Medicine, Inc. Main Business
Table 97. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 98. Editas Medicine, Inc. Latest Developments
Table 99. Grifols, S.A. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors
Table 100. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Offered
Table 101. Grifols, S.A. Main Business
Table 102. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 103. Grifols, S.A. Latest Developments
Table 104. Inhibrx Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors
Table 105. Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Offered
Table 106. Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 107. Inhibrx Main Business
Table 108. Inhibrx Latest Developments
Table 109. Intellia Therapeutics, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors
Table 110. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered
Table 111. Intellia Therapeutics, Inc. Main Business
Table 112. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 113. Intellia Therapeutics, Inc. Latest Developments
Table 114. International Stem Cell Corporation Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 115. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 116. International Stem Cell Corporation Main Business

Table 117. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 118. International Stem Cell Corporation Latest Developments

Table 119. Ionis Pharmaceuticals, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 120. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 121. Ionis Pharmaceuticals, Inc. Main Business

Table 122. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 123. Ionis Pharmaceuticals, Inc. Latest Developments

Table 124. Kamada Ltd. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 125. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 126. Kamada Ltd. Main Business

Table 127. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 128. Kamada Ltd. Latest Developments

Table 129. Polyphor Ltd. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 130. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 131. Polyphor Ltd. Main Business

Table 132. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 133. Polyphor Ltd. Latest Developments

Table 134. ProMetic Life Sciences Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 135. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 136. ProMetic Life Sciences Inc. Main Business

Table 137. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 138. ProMetic Life Sciences Inc. Latest Developments

Table 139. rEVO Biologics, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 140. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product

Offered

Table 141. rEVO Biologics, Inc. Main Business

Table 142. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 143. rEVO Biologics, Inc. Latest Developments

Table 144. Sangamo BioSciences, Inc. Details, Company Type, Alpha- Antitrypsin Deficiency Treatment Area Served and Its Competitors

Table 145. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Offered

Table 146. Sangamo BioSciences, Inc. Main Business

Table 147. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 148. Sangamo BioSciences, Inc. Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Alpha- Antitrypsin Deficiency Treatment Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate 2019-2030 (\$ Millions)
- Figure 6. Alpha- Antitrypsin Deficiency Treatment Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 7. Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country/Region (2023)
- Figure 8. Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 9. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type in 2023
- Figure 10. Alpha- Antitrypsin Deficiency Treatment in Clinic
- Figure 11. Global Alpha- Antitrypsin Deficiency Treatment Market: Clinic (2019-2024) & (\$ Millions)
- Figure 12. Alpha- Antitrypsin Deficiency Treatment in Hospital
- Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Market: Hospital (2019-2024) & (\$ Millions)
- Figure 14. Alpha- Antitrypsin Deficiency Treatment in Others
- Figure 15. Global Alpha- Antitrypsin Deficiency Treatment Market: Others (2019-2024) & (\$ Millions)
- Figure 16. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application in 2023
- Figure 17. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Player in 2023
- Figure 18. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Regions (2019-2024)
- Figure 19. Americas Alpha- Antitrypsin Deficiency Treatment Market Size 2019-2024 (\$ Millions)
- Figure 20. APAC Alpha- Antitrypsin Deficiency Treatment Market Size 2019-2024 (\$ Millions)
- Figure 21. Europe Alpha- Antitrypsin Deficiency Treatment Market Size 2019-2024 (\$ Millions)

Figure 22. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size 2019-2024 (\$ Millions)

Figure 23. Americas Alpha- Antitrypsin Deficiency Treatment Value Market Share by Country in 2023

Figure 24. United States Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 25. Canada Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 26. Mexico Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 27. Brazil Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 28. APAC Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Region in 2023

Figure 29. APAC Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type in 2023

Figure 30. APAC Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application in 2023

Figure 31. China Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 32. Japan Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 33. Korea Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 34. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 35. India Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 36. Australia Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 37. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Country in 2023

Figure 38. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

Figure 39. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

Figure 40. Germany Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 41. France Alpha- Antitrypsin Deficiency Treatment Market Size Growth

2019-2024 (\$ Millions)

Figure 42. UK Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 43. Italy Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 44. Russia Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 45. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Region (2019-2024)

Figure 46. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

Figure 47. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Application (2019-2024)

Figure 48. Egypt Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 49. South Africa Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 50. Israel Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 51. Turkey Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 52. GCC Country Alpha- Antitrypsin Deficiency Treatment Market Size Growth 2019-2024 (\$ Millions)

Figure 53. Americas Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 54. APAC Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 55. Europe Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 56. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 57. United States Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 58. Canada Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 59. Mexico Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 60. Brazil Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 61. China Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 62. Japan Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 63. Korea Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 64. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 65. India Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 66. Australia Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 67. Germany Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 68. France Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 69. UK Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 70. Italy Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 71. Russia Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 72. Spain Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 73. Egypt Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 74. South Africa Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 75. Israel Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 76. Turkey Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 77. GCC Countries Alpha- Antitrypsin Deficiency Treatment Market Size 2025-2030 (\$ Millions)

Figure 78. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share Forecast by Type (2025-2030)

Figure 79. Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Alpha- Antitrypsin Deficiency Treatment Market Growth (Status and Outlook) 2024-2030

Product link: <https://marketpublishers.com/r/G1319C0229CDEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1319C0229CDEN.html>